Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, has obtained a $200 million non-dilutive term loan...
Read Story
November 11, 2024, 08:08 AM
|
SSG Capital Advisors served as the investment banker to Eiger BioPharmaceuticals, Inc. in the sale of Lonafarnib and Lambda, and associated clinical assets to Eiger InnoTherapeutics, Inc. The sale was effectuated through a Chapter 11 Section 363...
Read Story
September 13, 2024, 07:47 AM
|
iBio, an AI-driven innovator of precision antibody immunotherapies, announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank, have entered into an amendment to the Credit Agreement dated November 1, 2021...
Read Story
December 27, 2023, 07:00 AM
|
Clovis Oncology, a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, announced that it and certain of its subsidiaries...
Read Story
December 12, 2022, 08:00 AM
|
Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, secured a term loan facility of up to $125 million with Hercules Capital.The term loan facility provides for up to $125 million of term...
Read Story
September 01, 2022, 07:50 AM
|
Savara, a clinical stage biopharmaceutical company focused on rare respiratory diseases, entered into a term loan agreement of $26.5 million with Silicon Valley Bank to replace its existing credit facility with the bank. The new facility represents a...
Read Story
April 25, 2022, 07:29 AM
|
Xeris Biopharma Holdings entered into a senior secured term loan agreement with funds managed by Hayfin Capital Management to provide Xeris with up to a total of $150 million of capital.Under the terms of the debt facility, Xeris drew down $100...
Read Story
March 10, 2022, 07:49 AM
|
Mustang Bio, a clinical-stage biopharmaceutical company announced completion of a $75 million long-term debt facility with Runway Growth Capital, a leading provider of growth loans to both venture and non-venture backed companies seeking an...
Read Story
March 09, 2022, 07:51 AM
|
Amryt, a global, commercial-stage biopharmaceutical company secured $125 million of senior credit facilities from funds managed by the Credit Group of Ares Management Corporation. Amryt will use a portion of the proceeds to refinance its previous...
Read Story
February 23, 2022, 07:18 AM
|
Liquidia Corporation closed a debt facility on January 7, 2022, with Silicon Valley Bank (SVB) which provides Liquidia with up to $40.0 million in term loans of which the first $20.0 million was funded at closing. Liquidia initially entered a debt...
Read Story
January 10, 2022, 08:00 AM
|
Corium, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, closed on a $235 million term loan agreement with Hercules Capital. Corium will receive an initial...
Read Story
September 29, 2021, 07:32 AM
|
Aptinyx, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds...
Read Story
September 16, 2021, 07:42 AM
|
Analysis by Tiger Liquidity Services Biopharma Partnership underscores the strategic value to hedge funds, private equity firms, asset-based lenders, and bankruptcy professionals of leveraging asset-valuation and disposition in the...
Read Story
June 02, 2020, 09:05 AM
|
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading global investment firm...
Read Story
January 07, 2019, 07:20 AM
|
Tiger Group and Liquidity Services, Inc. announced the launch of a partnership focused on rapid, efficient and high-recovery disposition of assets from distressed organizations in the biopharmaceutical manufacturing industry.
Tiger Liquidity...
Read Story
November 14, 2018, 08:13 AM
|
Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, has entered into a new secured credit facility with Silicon Valley Bank (SVB), the bank of the...
Read Story
March 02, 2018, 07:16 AM
|
Wells Fargo Securities, the investment banking and capital markets business of Wells Fargo & Company, announced that Andrew Singer has joined as managing director focused on the biopharmaceutical industry. He will be based in San Francisco. “We are...
Read Story
November 15, 2017, 07:25 AM
|
Motif Bio plc, a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announced that the company has entered into an agreement for up to $20 million in debt financing with Hercules Capital, Inc. a provider of debt...
Read Story
November 15, 2017, 07:01 AM
|
Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, announced that it has entered into credit and...
Read Story
July 19, 2017, 07:00 AM
|
Square 1 Bank, a division of Pacific Western Bank, announced that it has provided a $15 million credit facility to new client Unum Therapeutics, a clinical stage biopharmaceutical company developing cellular immunotherapies for the treatment of many...
Read Story
March 15, 2017, 07:39 AM
|
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, has entered into a long-term loan and security agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. for up to $40...
Read Story
February 09, 2016, 07:27 AM
|
Omeros Corporation closed a senior credit facility with Oxford Finance and MidCap Financial consisting of a $32 million term loan, which requires interest-only payments through March 2015. Thereafter, monthly principal and interest payments will be...
Read Story
March 06, 2014, 07:14 AM
|
ADMA Biologics, Inc. announced it has secured a loan commitment for up to $15 million from Hercules Technology Growth Capital, Inc., a leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in...
Read Story
February 28, 2014, 07:19 AM
|